Company news

Xenetic Biosciences, Inc. news in 2023

Xenetic Biosciences, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results

November 9, 2023

Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference

October 10, 2023

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 4, 2023

Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results

August 10, 2023

Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series

July 4, 2023

Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock

May 11, 2023

Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

May 10, 2023

Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development

May 3, 2023

Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison

May 2, 2023

Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

April 10, 2023

Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update

March 22, 2023

Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event

March 15, 2023

Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy

January 16, 2023

Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event

January 4, 2023

Decks in 2023